nep_2.fm Page 5 Friday, January 26, 200 6:46 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology120-558 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 20012S1584MiscellaneousCalcineurin Inhibitors in Renal TransplantationThe CARI Guidelines NEPHROLOGY 200; 12, S5S84 doi:10.1111/j.1440-19.2006.002.x The addition of anti-cd25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients Date written: November 2005 Final submission: October 2006 Author: Angela C Webster SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on Level III and IV evidence) No recommendation. BACKGROUND Interleukin 2 (IL2)-mediated activation of lymphocytes is a critical pathway in the cellular immune response of acute kidney transplant rejection. Anti-CD25 antibodies (anti- CD25ab, also known as IL2 receptor antagonists (IL2RA)) are humanized or chimeric IgG monoclonal antibodies to the alpha subunit of the CD25 receptor present only on activated T lymphocytes and competitively antagonize this IL2-mediated activation. 1,2 The rationale for using anti-cd25ab has been as induction agents in the peri-transplant period, used together with standard agents to try to minimize early graft injury by preventing acute rejection or to minimize exposure to the calcineurin inhibitors (particularly in recipients deemed at high risk of delayed initial graft function), thereby ameliorating the short- and long-term nephrotoxic side-effects of both cyclosporin and tacrolimus.,4 Anti-CD25ab are commercially available as basiliximab and daclizumab. The use of anti-cd25ab has increased globally since their introduction in the mid-1990s, with 8% of new kidney transplant recipients in the United States, and 2% in Australasia receiving IL2RA in 2002. In Australia and New Zealand, the widespread use of anti-cd25ab is limited by local funding arrangements and variability in clinical practice. 5,6 Correspondence: Angela C Webster, Department of Renal Medicine, Royal Infirmary of Edinburgh, Old Dalkeith Road, Edinburgh EH16 4SY, UK. Email: angela.webster@ gmail.com 200 The Author Journal compilation 200 Asian Pacific Society of Nephrology GUIDELINES a. Addition of anti-cd25 antibody to calcineurin inhibitor-based therapy is recommended as it confers significant benefit in reducing acute allograft rejection in kidney transplant recipients. (Level I evidence) b. For induction therapy, anti-cd25 antibodies should be considered in preference to either mono- or polyclonal, T-cell depleting antibody preparations as they are as efficacious but have significantly fewer side-effects. (Level I evidence) c. Basiliximab and daclizumab are equally effective. (Level I evidence) SEARCH STRATEGY Databases searched: MeSH terms and text words for kidney transplantation and monoclonal antibody were combined with MeSH terms and text words for the intervention. The results were then combined with the Cochrane search strategy for randomized controlled trials and MeSH terms and text words for identifying meta-analyses and systematic reviews. The search was carried out in Medline (1966 October 200). The Cochrane Renal Group Specialized Register of randomized controlled trials was also searched for relevant trials not indexed in Medline. Date of search: October 2005. WHAT IS THE EVIDENCE? Cochrane review A Cochrane review was published in January 2004 of anti- CD25ab for treatment of renal transplant recipients. This meta-analysis included a total of 11 reports (publications and abstracts) of 8 trials representing a total of 489 randomized participants. Table 1 details these trials. The objectives of this review were to systematically identify and summarize the effects of anti-cd25ab as induction agents: as an addition to standard triple therapy with a calcineurin inhibitor, anti-proliferative agent and steroids, and as an alternative to other antibody therapies in common use (i.e. anti-thymocyte globulins (ATG), anti-lymphocyte globulins (ALG), monomurab-cd). The review excluded trials where participants received another transplant organ in addition to a kidney transplant. This review searched Medline, EMBASE, Cochrane sources and conference proceedings from inception to November 2002.
nep_2.fm Page 6 Friday, January 26, 200 6:46 PM S6 The CARI Guidelines Sixteen trials (2682 participants) compared an anti- CD25ab with placebo or no treatment and 14 trials (1108 participants) compared anti-cd25ab with another monoor polyclonal antibody (either monomurab-cd, ATG or ALG). One trial with three arms (156 participants) compared an anti-cd25ab with both no treatment and a polyclonal antibody. Two trials (82 participants) compared basiliximab with daclizumab, and the remaining five trials involved anti-cd25ab in a unique comparison (different dosing of the same anti-cd25ab, anti-cd25ab within a calcineurin inhibitor-free regimen and anti-cd25ab within a steroid-reduced or steroid-free regimen). Summary estimates were expressed as relative risk (RR), with values <1 favouring treatment with anti-cd25ab. Anti-CD25ab + standard therapy compared with standard therapy Results were homogeneous across all outcomes, with no differences demonstrated between the different anti-cd25ab used and the differing combinations of additional immunosuppressants. Graft loss favoured the use of anti-cd25ab, but was not significantly different at (14 trials, RR 0.8, 95% CI: 0.661.04) or (4 trials, RR 0.88, 95% CI: 0.641.22). The incidence of clinically diagnosed acute rejection within of transplantation was reduced by 4% for those treated with an anti-cd25ab (12 trials, RR 0.66, 95% CI: 0.590.4) and at (10 trials, RR 0.6, 95% CI: 0.600.5). Figure 1 shows the forest plot. This advantage was similar for biopsy-proven rejection, showing a 6% reduction. Treatment with an anti-cd25ab showed a substantial effect in preventing steroid-resistant rejection, reducing incidence at by 49% ( trials, RR 0.51, 95% CI: 0.80.6). Cytomegalovirus infection was reduced in anti-cd25ab-treated patients, but did not reach statistical significance ( trials, RR 0.82, 95% CI: 0.65 1.0). All other outcomes favoured the use of anti-cd25ab, but none reached statistical significance. Table 2 details the results of the meta-analysis. Anti-CD25ab + standard therapy compared with other mono- or polyclonal antibody preparations + standard therapy The comparative efficacy of different IL2RA preparations The two trials comparing basiliximab and daclizumab headto-head were small (n = 82 total) and data could not be combined. Indirect comparison, by subgrouping trials by their intervention (daclizumab or basiliximab), showed no difference for any outcomes. Adding basiliximab to a double or triple therapy regimen had the same benefit as adding daclizumab in preventing acute rejection at (basiliximab: RR 0.6, 95% CI: 0.590. vs daclizumab: RR 0.66, 95% CI: 0.50.). Other systematic reviews A smaller systematic review and meta-analysis of anti- CD25ab in renal transplantation was published in April 200. 8 This meta-analysis was limited to eight randomized trials comparing the addition of anti-cd25ab to cyclosporin-based immunosuppression with cyclosporinbased therapy alone. This review searched Medline, EMBASE, Cochrane sources and conference proceedings from inception to 200. Summary estimates were expressed as odds ratio (OR), with values <1 favouring treatment with anti-cd25ab. The effect on acute rejection was similar for all types of anti-cd25ab, and there was no evidence of heterogeneity of effect between any baseline immunosuppressive regimens or between trials for any other outcomes. The composite outcome of graft loss or death with a functioning graft favoured the use of anti-cd25ab but was not significantly different at (8 trials, OR 0.8, 95% CI: 0.581.04). The incidence of biopsy-proven acute rejection within of transplantation was significantly reduced (8 trials, OR 0.51, 95% CI: 0.420.6). Subsequent randomized trials A Medline search in October 2005 for randomized trials reported since the publication of both systematic reviews revealed only one new trial and four further additional reports of trials already included in the Cochrane review. The results of the new trial 9 concur with those included in the Cochrane review. Anti-CD25ab was equally effective as other mono- and polyclonal antibodies in preventing acute rejection (Figure 2 shows the forest plot). No statistically significant differences in treatment effect were demonstrated for graft loss, mortality, cytomegalovirus infection or malignancy. Adverse reactions to the study drug were not widely reported, but statistically significant differences were shown for fever (4 trials, RR 0.4, 95% CI: 0.11.00), leucopaenia (5 trials, RR 0.21, 95% CI: 0.100.46), thrombocytopaenia (4 trials, RR 0.26, 95% CI: 0.160.41) and overall adverse reactions (4 trials, RR 0.8, 95% CI: 0.10.86), in favour of IL2RA compared with other antibody therapies. Table 2 details the results of the meta-analysis. Economic evaluations Eight journal publications were identified that examined the health economic implications of the addition of anti- CD25ab to standard immunosuppression, from the health system perspective. Seven were costbenefit analyses using data from randomized trials: five of the addition of an anti- CD25ab to standard therapy compared with standard therapy alone, and two looked at the use of an anti-cd25ab compared with another mono- or polyclonal antibody, one of which also included a cost-utility analysis. The final publication used results from two randomized trials to project costs in a country where no randomized trial had been
nep_2.fm Page Friday, January 26, 200 6:46 PM Calcineurin Inhibitors in Renal Transplantation S undertaken. None of these publications used trial data from Australasian centres. These publications are summarized in Table. None of the evaluations performed alongside randomized trials showed a statistically significant saving or additional expense when an anti-cd25ab was used, either in addition to standard therapy or instead of a different mono- or polyclonal antibody therapy. Only one evaluation incorporated a Quality of Life function, and again, this was no different for those treated with anti-cd25ab. WHAT DO THE OTHER GUIDELINES SAY? International Guidelines: Kidney Disease Outcomes Quality Initiative: No recommendation. UK Renal Association: 10 At the moment there are insufficient data to permit specific recommendations on the various immunosuppressive regimens involving monotherapy, double or triple therapy using prednisolone, azathioprine, cyclosporin microemulsion (Neoral TM), tacrolimus, mycophenolate mofetil or rapamycin. Nor is the role of antibody therapies (basiliximab, dacluzimab, antilymphocyte globulin, OKT, etc.) clear. It is likely that mycophenolate mofetil, anti CD25 antibodies and rapamycin will become increasingly used during the next few years because the number of early rejections using regimens, which include these drugs, appear to be lower, and lower rates of early rejection in turn are correlated with better long-term function and graft survival. Canadian Society of Nephrology: No recommendation. European Best Practice Guidelines: 11 Recently safe and effective prophylactic therapy has been achieved with high affinity humanized or chimeric monoclonal antibodies (daclizumab and basiliximab) which target the IL2 receptor. British Transplant Society: Guidelines for the Management of the Non-Heart Beating Solid Organ Donor. 12 It is logical to try to minimise further nephrotoxic injury to the renal transplant. Initial treatment with IL-2 receptor blockers, prednisolone and mycophenolate mofetil with the introduction of tacrolimus when there is either graft function with a creatinine below an arbitrary level of say 50 micromol/l or there is evidence of rejection is practiced by some units. National Institute for Health and Clinical Excellence United Kingdom: 1 Basiliximab or daclizumab, used as part of a calcineurin-inhibitor-based immunosuppressive regimen, are recommended as options for induction therapy in the prophylaxis of acute organ rejection in adults undergoing renal transplantation. The induction therapy (basiliximab or daclizumab) with the lowest acquisition cost should be used. IMPLEMENTATION AND AUDIT No recommendation. SUGGESTIONS FOR FUTURE RESEARCH Despite the large number of randomized trials, there was under-representation of high risk participants and children overall. Future trials involving patients at higher baseline risk for transplantation would confirm the benefits in this subgroup. Follow up prolonged beyond would inform longer-term outcomes and adverse effects more fully. CONFLICT OF INTEREST Angela Webster has no relevant financial affiliations that would cause a conflict of interest according to the conflict of interest statement set down by CARI. REFERENCES 1. Goebel J, Stevens E, Forrest K et al. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl. Immunol. 2000; 8: 159. 2. Cibrik DM, Kaplan B, Meier-Kriesche HU. Role of antiinterleukin-2 receptor antibodies in kidney transplantation. Biodrugs 2001; 15: 65566.. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 5: 10891. 4. Pascual J, Marcen R, Ortuno J. Anti-interleukin-2 receptor antibodies: Basiliximab and daclizumab. Nephrol. Dial Transplant. 2001; 16: 15660. 5. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Available from URL: http://www.anzdata.org.au/ ANZDATA/anzdatawe/come.htm. Accessed February 200. 6. United Network for Organ Sharing (UNOS). OPTN data. Available from URL: http://www.optn.org. Accessed 25 July 200.. Webster AC, Playford EG, Higgins G et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst. Rev. 2004; 1: CD0089. 8. Adu D, Cockwell P, Ives NJ et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. BMJ 200; 26: 899. 9. Bingyi S, Yeyong Q, Ming C et al. Randomised trial of simulect versus placebo for control of acute rejection in renal allograft recipients. Transplant. Proc. 200; 5: 1924. 10. British Renal Association. Treatment of adults and children with renal failure: standards and audit measures (rd edition). Chapter 8, p. 104. London: Royal College of Physicians of London and the Renal Association, 2002. 11. European best practice guidelines. Nephrol. Dial. Transplant. 2000; 15: 606. 12. British Transplant Society. Guidelines relating to solid organ transplants from non-heart beating donors. Available from URL: http://www.bts.org.uk/forms/guidelinesnov2004.pdf 1. National Institute for Health & Clinical Excellence United Kingdom. Immunosuppressive therapy for renal transplantation in adults. NICE Technology Appraisal 85, September 2004. Available from URL: http://www.nice.org.uk/ta085/ 14. Keown PA, Balshaw R, Krueger H et al. Economic analysis of basiliximab in renal transplantation. Transplantation 2001; 1: 159. 15. Lorber MI, Fastenau J, Wilson D et al. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin. Transplant. 2000; 14: 4985.
nep_2.fm Page 8 Friday, January 26, 200 6:46 PM S8 The CARI Guidelines 16. Walters SJ, Whitfield M, Akehurst RL et al. Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients. Transplant. Proc. 2001; : 1891. 1. Chilcott JB, Holmes MW, Walters S et al. The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. Transplant Int. 2002; 15: 4869. 18. Polsky D, Weinfurt KP, Kaplan B et al. An economic and qualityof-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. Nephrol. Dial. Transplant. 2001; 16: 1028. 19. Lilliu H, Brun-Strang C, Le Pen C et al. Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction. Clin. Transplant. 2004; 18: 245. 20. Hasegawa T, Imai H, Miki S. Cost evaluation of basiliximab treatment for renal transplant patients in Japan. Pharmacoeconomics 200; 21: 91806.
nep_2.fm Page 9 Friday, January 26, 200 6:46 PM Calcineurin Inhibitors in Renal Transplantation S9 APPENDICES Table 1 Characteristics of trials included in systematic review by Webster et al. 2004 Trial ID (author, year) n Cadaveric donor (%) First transplant (%) IL2RA (n) Comparator (n) Calcineurin inhibitor (initial dose, mg/kg/d: trough, ng/ml) Co-interventions Duration of Antiproliferative agent (Aza mg/kg/d, MMF g/d) Il2RA vs placebo/no treatment Ahsan, 2002 100 0 100 Daclizumab (50) None (50) T (0.160.20: 1015) MMF (1) 1 Baczkowska, 2002 2 ns ns Daclizumab (16) None (16) Cy (510: ns) MMF (2) 0. Daclizumab double, 1999 25 100 100 Daclizumab (141) Placebo (14) Cy (10: ns) Daclizumab triple, 1998 260 100 100 Daclizumab (126) Placebo (14) Cy (ns: ns) Aza (ns) Davies/Lawen, 2000 12 6 89 Basiliximab (59) Placebo (64) Cy (810: 100400) MMF (2) 1 de Boccardo, 2002 10 45 ns Basiliximab (ns) Placebo (ns) Cy (10: ns) Aza (12) 0.5 Folkmane, 2001 1 100 ns Basiliximab (2) None (2/25) Cy (ns: 15000) Aza (12) or MMF (2) 1 Kahan, 1999 46 0 100 Basiliximab (1) Placebo (1) Cy (ns: 150450) 1 Kirkman, 1991 80 ns 100 Anti-TAC (40) None (40) Cy (48: ns) Aza (2) 1 Kirkman, 1989 21 100 100 Anti-TAC (12) None (9) Cy (812: ns) or Aza (2) 1 Kyllonen, 2002 104 100 ns Basiliximab (52) None (52) Cy (5: ns) Aza or MMF (ns) 1 Nashan, 199 6 100 100 Basiliximab (190) Placebo (186) Cy (ns: 150450) 1 Pisani, 2001 2 ns 81 Basiliximab (10/9) None (1) Cy (8: 50400) MMF (1.5) 0.5 Ponticelli, 2001 40 8 9 Basiliximab (168) Placebo (12) Cy (10: 15000) Aza (12) 1 Sandrini, 2002 156 ns 100 Basiliximab (9) Placebo () Cy (ns: ns) Aza (ns) 1 Sheashaa, 200 100 0 100 Basiliximab (50) None (50) Cy (8: 125150) Aza (1) van Gelder, 1996 60 8 100 BT56 (0) Placebo (0) Cy (8: 00) Il2RA vs other antibody Brennan, 2002 212 100 ns Basiliximab (106) ATG (106) Cy (1216: ns) MMF (2) 0.5 Flechner, 2000 45 ns ns Basiliximab (2) OKT (22) Cy (ns: ns) MMF (2) 0.5 Hourmant, 1994 40 ns 0 B.1 (20) ATG (20) Cy (8: 150250) Aza (2) 1 Kriaa, 199 40 100 ns Lo-tact-1 (20) ALG (20) Cy (8: ns) Aza (1) 1 Kyllonen, 2002 104 100 ns Basiliximab (52) ATG (52) Cy (5: ns) Aza or MMF (ns) 1 Lacha, 2001 28 ns 58 Daclizumab (14) OKT (14) Cy (8: ns) MMF (2) 0.5 follow up (years) Additional immunosuppressive agents. All trials (except van Riemsdijk 2002 and ATLAS 200) also used steroid therapy in all arms. Trials ongoing. Kyllonen 2002 (156 participants) has three arms comparing IL2RA both with no treatment and with ATG, and so appears in both comparisons. ALG, anti-lymphocyte globulins; ATG, anti-thymocyte globulins; Aza, azathioprine; Cy, cyclosporin; IL2RA, IL2 receptor antagonists; MMF, mycophenolate mofetil; ns, not stated; P, steroid; T, tacrolimus;, no agent used.
nep_2.fm Page 80 Friday, January 26, 200 6:46 PM S80 The CARI Guidelines Table 1 Continued Trial ID (author, year) n Cadaveric donor (%) First transplant (%) IL2RA (n) Comparator (n) Lebranchu, 2002 10 100 100 Basiliximab (52) ATG (51) Cy (68: 150200) MMF (2) 1 Mourad, 2002 89 98.5 89.5 Basiliximab (46) ATG (4) Cy (6: ns) MMF (2) 0.5 Philosophe, 2002 50 ns 92 Daclizumab (26) OKT (24) T (ns: ns) MMF (ns) 1 Poufarziani, 200 25 0 0 Daclizumab (11) ALG (14) Cy (ns: ns) MMF (ns) 1 Shidban, 2000 42 100 ns Basiliximab (22) OKT (20) Cy (ns: ns) MMF (ns) 0.5 Shidban, 200 5 100 100 Basiliximab (25) ATG (50) Cy (ns: ns) MMF (ns) 0.5 Sollinger, 2001 15 62 81 Basiliximab (0) ATG (65) Cy (610: ns) MMF (2) 1 Soulillou, 1990 100 100 100 B.1 (50) ATG (50) Cy (8: 00600) Aza (2) 1 Tullius, 200 124 100 5 Basiliximab (62) ATG (62) T (0.2: 10) 1 IL2RA vs other comparisons Garcia, 2002 49 0 100 Daclizumab, MMF(2) T, Aza (26) T (0.100.15: ns), MMF (2), Aza (2) 0.5 Khan, 2000 59 ns ns Basiliximab (29) Daclizumab (0) T or Cy (ns) MMF (ns) or Aza (ns) 0.25 ATLAS, 200 45 ns ns Basiliximab (15) MMF (151); MMF/P (14) Kumar, 2002 2 ns ns High Basiliximab, low P (1) Matl, 2001 202 100 100 Basiliximab (102) standard Basiliximab, normal P (10) Basiliximab (100) 1 high Calcineurin inhibitor (initial dose, mg/kg/d: trough, ng/ml) Co-interventions Duration of Antiproliferative agent (Aza mg/kg/d, MMF g/d) T (0.2: 515) MMF (2) 0.5 Cy (ns: ns) MMF (ns) 1 Cy (10: ns), Aza (12) 1 Nair, 2001 2 26 100 Basiliximab (10) Daclizumab (1) Cy (: ns) MMF (2) 0.5 van Riemsdijk, 2002 10 ns ns Daclizumab, no P (64) P (66) T (ns: ns) MMF (ns) 0.5 follow up (years) Additional immunosuppressive agents. All trials (except van Riemsdijk 2002 and ATLAS 200) also used steroid therapy in all arms. Trials ongoing. Kyllonen 2002 (156 participants) has three arms comparing IL2RA both with no treatment and with ATG, and so appears in both comparisons. ALG, anti-lymphocyte globulins; ATG, anti-thymocyte globulins; Aza, azathioprine; Cy, cyclosporin; IL2RA, IL2 receptor antagonists; MMF, mycophenolate mofetil; ns, not stated; P, steroid; T, tacrolimus;, no agent used.
nep_2.fm Page 81 Friday, January 26, 200 6:46 PM Calcineurin Inhibitors in Renal Transplantation S81 Table 2 Outcomes of meta-analysis and systematic review by Webster et al. 2004 Outcome Number of trials Number of participants Relative risk (95% CI) Test for heterogeneity P-value IL2RA vs placebo/no treatment Acute rejection (all) months 12 10 16 240 2052 0.54 (0.25, 1.16) 0.66 (0.59, 0.4) 0.6 (0.60, 0.5) 0.8 0.99 0.98 Acute rejection (biopsy proven) months 1 10 6 222 1820 0.42 (0.12, 1.45) 0.64 (0.56, 0.) 0.6 (0.59, 0.6) 0.9 0.90 Acute rejection (steroid resistant) months 1 55 154 46 0.15 (0.01, 2.4) 0.51 (0.8, 0.6) 0.62 (0.46, 0.84) 0.91 0.46 Graft loss censored for death 6 14 4 9 2410 695 0.9 (0.49, 1.2) 0.84 (0.64, 1.10) 1.0 (0.1, 1.59) 0.8 0.9 0.54 Graft loss or death 14 4 1081 2410 695 0. (0.52, 1.15) 0.8 (0.66, 1.04) 0.88 (0.64, 1.22) 0.88 0. 0.82 Mortality (all cause) 6 1 4 9 29 695 0.84 (0.0, 1.84) 0.8 (0.4, 1.40) 0.5 (0.25, 1.0) 0.88 0.2 0.1 CMV infection 1208 1528 0.92 (0.0, 1.20) 0.82 (0.65, 1.0) 0.1 0.6 Malignancy (all) 4 9 1040 1861 65 0.45 (0.09, 2.1) 0.6 (0., 1.6) 0.8 (0.45, 1.5) 0.6 0.44 0.49 Delayed graft function 9 180 0.8 (0.2, 1.06) 0.2 IL2RA vs other antibody Acute rejection (all) Acute rejection (biopsy proven) Acute rejection (steroid resistant) Graft loss censored for death Graft loss or death Mortality CMV infection Malignancy (all) months months months 6 9 5 5 2 8 8 8 6 4 1 1 60 8 449 195 564 15 26 299 521 620 625 618 49 59 498 299 212 15 1.05 (0.4, 1.51) 0.99 (0.1, 1.9) 0.92 (0.68, 1.24) 1.14 (0., 1.6) 1.1 (0.86, 1.99) 0.9 (0.61, 1.5) 1.10 (0.55, 2.20) 1.09 (0.56, 2.10) 1.18 (0.54, 2.56) 0.9 (0.45, 2.10) 1.52 (0.80, 2.88) 1.16 (0.59, 2.25) 2.09 (0.68, 6.42) 1.96 (0.9, 4.90) 0.58 (0.22, 1.52) 0.69 (0.0, 1.56) 0. (0.04,.15) 0.1 (0.0, 2.90) 0. 0.28 0.94 0.96 0.9 0.8 0.42 0.28 0.9 0.0 0. 0.18 0.88 0.85 0.005 0.24 Adverse reaction to drug 4 45 0.8 (0.10, 0.46) 0.00 Fever 4 281 0.41 (0.1, 1.00) 0.0 Leucopaenia 5 52 0.21 (0.10, 0.46) 0.15 Thrombocytopaenia 4 41 0.26 (0.16, 0.41) 0.41 Delayed graft function 8 645 1. (1.02, 1.84) 0.19 Relative risk values of less than 1 favour treatment with an IL2RA. Significant benefit for IL2RA demonstrated. Delayed graft function, requirement for dialysis within 1st week post transplantation. CI, confidence interval; CMV, cytomegalovirus; IL2RA, IL2 receptor antagonists.
nep_2.fm Page 82 Friday, January 26, 200 6:46 PM S82 The CARI Guidelines Table Economic evaluations of anti-cd25 antibody Study ID (author, year) Trial name Setting of trial Setting of economic analysis Analysis type Conclusion Evaluations based on randomized trial data, AntiCD-25ab + standard therapy compared with standard therapy alone Keown, 2001 14 Nashan 199 Costbenefit over 1st year Lorber, 2000 15 Kahan 1999 Walters, 2001 16 Ponticelli 2001 Chilcott, 2002 1 Nashan 199 Canada, UK, Germany, Belgium, Switzerland, Norway Canada, 19941999 expressed in Canadian $ USA USA, 199 Costbenefit over 1st year Belgium, Finland, France, Israel, Italy, Mexico, Poland, South Africa, Turkey, UK, Germany, Spain Canada, UK, Germany, Belgium, Switzerland, Norway Resource use from each country pooled, expressed in US$, 1991998 Resource use from each country pooled, as no difference shown, expressed in US$, 199 Costbenefit over Costbenefit over 1st year Before accounting for the cost of the anti-cd25 itself, basiliximab produces a saving of C$4554 during the 1st year, the majority due to reduced costs of graft dysfunction and follow up of hospitalizations. When accounting for the market cost of therapy this is likely to result in net saving C$1554 per patient in the 1st year. Direct medical costs over the first year showed saving for basiliximab US$, the difference is not statistically significant. Costbenefit over first show basiliximab patients cost US$649 more than placebo, due to cost of basiliximab, and the difference is not statistically significant. Overall, basiliximab-treated patients show increased costs of US$1660 compared with placebo, but this difference is not statistically significant. There is a 24% chance basiliximab will be cost-saving in the first year. The difference did not vary significantly by country. Overall costs 21 higher for basiliximab patients in the first, a non-significant difference, but showing a 0 saving over 12 months. Walters, 200 16 Ponticelli 2001 Belgium, Finland, France, Israel, Italy, Mexico, Poland, South Africa, Turkey, UK, Germany, Spain Resource use from each country pooled, as no difference shown, and expressed in UK sterling, 1991999 Costbenefit over 1st year Evaluations based on randomized trial data, AntiCD-25ab + standard therapy compared with other antibody + standard therapy Polsky, 2001 18 Sollinger USA USA, 199 Costbenefit, 2001 and cost utility over 1st year Lilliu, 2004 19 Lebranchu 2002 France France, expressed in Euros Cost minimization over Costbenefit for basiliximab over ATG of US$ 882, mostly due to decreased costs of therapy itself and initial hospitalization. Quality of life scores were not significantly different over the first year, and quality-adjusted life year 81.5 for ATG and 81.1 for basiliximab patients. Cost saving of 1159 for basiliximab over ATG (thymoglobulin), mostly due to decreased costs associated with infectious episodes, which was statistically significantly lower in basiliximab group. Modelled cost projections, anti-cd25ab + standard therapy compared with standard therapy alone Hasegawa, 200 20 based on results from Nashan 199 and Kahan 1999 Japan, 2000 expressed in Yen Cost projection modelling A saving of 15 80 for basiliximabtreated patients, without including drug cost, the major benefit arising from decreased rejection treatment and dialysis. Quality-adjusted life year of 100 represents 100% survival in perfect health. ATG, anti-thymocyte globulins.
nep_2.fm Page 8 Friday, January 26, 200 6:46 PM Calcineurin Inhibitors in Renal Transplantation S8 Fig. 1 Anti-CD25 antibody + standard therapy vs standard therapy for outcome of acute rejection up to after transplantation. CI, confidence interval; IL2RA, IL2 receptor antagonists (anti-cd25 antibody); RR, relative risk.
nep_2.fm Page 84 Friday, January 26, 200 6:46 PM S84 The CARI Guidelines Fig. 2 Anti-CD25 antibody + standard therapy vs other mono- or polyclonal antibody + standard therapy for outcome of acute rejection within of transplantation. ALG, anti-lymphocyte globulins; ATG, anti-thymocyte globulins; CI, confidence interval; IL2RA, IL2 receptor antagonists (anti-cd25 antibody); RR, relative risk.